Shots:
The first patient was dosed in a bridging head-to-head study to evaluate the efficacy of Hansizhuang (serplulimab) vs atezolizumab in the US patient (n= 100) with ES-SCLC based on the positive feedback from the US FDA for BLA submission of Hansizhuang
In Apr 2022, Hansizhuang received ODD from the US FDA and also NDA has been accepted by the NMPA for Hansizhuang + CT to treat 1L ES-SCLC
In Mar 2022, Hansizhuang (a mAb) was launched in China for the treatment of MSI-H solid tumours and squamous non-small cell lung cancer
Ref: PRNewswire | Image: Henlius
